Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers
Authors:
- Roberto Ramos BarbosaRBRoberto Ramos Barbosa
- Taissa Borges BourguignonTBTaissa Borges Bourguignon
- Luíza Dias TorresLTLuíza Dias Torres
- Lorenza Silveira ArrudaLALorenza Silveira Arruda
- Tiago de Melo JacquesTJTiago de Melo Jacques
- Renato Giestas SerpaRSRenato Giestas Serpa
- Osmar de Araujo CalilOCOsmar de Araujo Calil
- Luiz Fernando Machado BarbosaLBLuiz Fernando Machado Barbosa
Open Access
- 1 August 2018
- journal article
- review article
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 64 (8) , 745-754
Abstract
SUMMARY OBJECTIVES This study aimed at assessing the role of beta-blockers on preventing anthracycline-induced cardiotoxicity in adults. METHODS A systematic review was performed on electronic databases, including relevant studies that analysed beta-blockers as cardioprotective agents before the use of anthracyclines by adult oncologic patients. RESULTS After application of eligibility and selection criteria, eight articles were considered as high quality, complying with the proposed theme; all eight clinical trials, four of them placebo-controlled, with a total number of 655 patients included. From this sample, 281 (42.9%) used beta-blocker as intervention, and carvedilol was the most frequent (167 patients – 25.5%). Six studies were considered positive regarding the cardioprotection role played by beta-blockers, although only four demonstrated significant difference on left ventricle ejection fraction after chemotherapy on groups that used beta-blockers compared to control groups. Carvedilol and nebivolol, but not metoprolol, had positive results regarding cardioprotection. Other beta-blockers were not analysed in the selected studies. CONCLUSIONS Despite the potential cardioprotective effect of beta-blockers, as demonstrated in small and unicentric clinical trials, its routine use on prevention of anthracycline-associated cardiotoxicity demands greater scientific evidence.Keywords
This publication has 35 references indexed in Scilit:
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- Cardiotoxicity and Cardioprotection in Childhood CancerActa Haematologica, 2014
- Prevention of Anthracycline-Induced CardiotoxicityJACC, 2014
- Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control studyInternational Journal of Cardiology, 2013
- Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant HemopathiesJACC, 2013
- Cardiotoxicity in Childhood Cancer Survivors: Strategies for Prevention and ManagementFuture Cardiology, 2012
- I Diretriz Brasileira de Cardio-Oncologia da Sociedade Brasileira de CardiologiaArquivos Brasileiros de Cardiologia, 2011
- Cardioprotective effect of metoprolol and enalapril in doxorubicin‐treated lymphoma patients: A prospective, parallel‐group, randomized, controlled study with 36‐month follow‐upAmerican Journal of Hematology, 2010
- Protective Effects of Carvedilol Against Anthracycline-Induced CardiomyopathyJACC, 2006
- Childhood cancer survival in Europe and the United StatesCancer, 2002